Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

Study of high school players find no link between years of play and decline in neurocognitive function

As more parents consider whether it's safe for adolescents to play football, a new Tulane University study of high school players found no link between years of play and any decline in neurocognitive function.

18 Mar 2014

Merck's NOXAFIL injection gets FDA approval for intravenous use

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved NOXAFIL (posaconazole) injection (18 mg/ mL), a new formulation of NOXAFIL for intravenous (IV) use.

16 Mar 2014

Study finds no link between neurocognitive function and years of football play in adolescent athletes

A new study presented today at the 2014 Annual Meeting of the American Academy of Orthopaedic Surgeons found no link between neurocognitive function and years of football play in adolescent athletes.

14 Mar 2014

Investigators urge drug regulators to provide clear evidence on statins’ side effects

At a time when the wider prescription of statins is under renewed public scrutiny, a substantial analysis of placebo-controlled randomised trials of statins has found that only a small minority of side effects reported by those taking the cholesterol-lowering drugs are actually attributable to them.

13 Mar 2014

Orexo signs multi-year agreement with OptumRx and UnitedHealth Group

Orexo AB, the manufacturer of ZUBSOLV® (buprenorphine and naloxone) sublingual tablets (CIII), announced a multi-year agreement with UnitedHealth Group® and OptumRx® providing preferred coverage and reimbursement of ZUBSOLV®.

12 Mar 2014

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma (HCC), or liver cancer, who had no detectable disease after surgical resection or local ablation, did not meet its primary endpoint of improving recurrence-free survival.

11 Mar 2014

Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma, Inc. today announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.

10 Mar 2014

New research reveals how substance abuse problems take hold in returning veterans

Of nearly 1 million veterans who receive opioids to treat painful conditions, more than half continue to consume opioids chronically or beyond 90 days, new research says. Results presented at the 30th Annual Meeting of the American Academy of Pain Medicine reported on a number of factors associated with opioid discontinuation with the goal of understanding how abuse problems take hold in returning veterans.

10 Mar 2014

Incyte Corporation publishes results of Phase III trial of ruxolitinib in patients with polycythemia vera

Incyte Corporation (Nasdaq: INCY) today announced that a pivotal Phase III trial of ruxolitinib compared to best available therapy in patients with polycythemia vera who are resistant to or intolerant of hydroxyurea has met its primary endpoint of achieving phlebotomy independence and reducing spleen size by 35 percent or more.

7 Mar 2014

Consumption of energy drinks may be linked with poor mental health, substance use among teens

The uplifting effects of energy drinks are well advertised, but a new report finds consumption among teenagers may be linked with poor mental health and substance use.

6 Mar 2014

Boehringer Ingelheim reports results from SVR12 Phase 3 trial in patients with HCV/HIV co-infection

Today Boehringer Ingelheim announced results from STARTVerso4 in patients with HCV/HIV co-infection. Hepatitis C viral cure 12 weeks after the conclusion of treatment (SVR12) was achieved by 72% of all patients in the trial. Patients were enrolled in either 120mg or 240mg faldaprevir dose groups.

6 Mar 2014

Metallic toys, low-cost jewelry can affect children's health

We know that babies and young children often put non-food items in their mouths, a behaviour that occasionally leads to swallowing of foreign objects. Metallic toys and low-cost jewelry often contain toxic substances such as lead and cadmium.

6 Mar 2014

Loyola surgeon successfully performs operation on patient suffering from rare disorder

Jarely Sanchez is an affectionate, energetic little girl who loves ballet. "Everyone she meets, she connects with," said her father, Jose Angel Ulloa. "She's like a magnet." But for more than a week, the three-year-old girl wasn't herself.

4 Mar 2014

New approach to breast reconstruction surgery decreases use of postoperative opioid painkiller

A new approach to breast reconstruction surgery aimed at helping patients' bodies get back to normal more quickly cut their postoperative opioid painkiller use in half and meant a day less in the hospital on average, a Mayo Clinic study found.

4 Mar 2014

AbbVie's PEARL-III study meets primary, secondary endpoints in patients with chronic GT1b HCV infection

The first detailed results from AbbVie's pivotal phase III study, PEARL-III, were presented today as part of the 21st Conference on Retroviruses and Opportunistic Infections (CROI) press conference and will also be presented as a late-breaker at the conference on March 4.

4 Mar 2014

Dendreon plans to make PROVENGE available in Europe

Dendreon Corporation today announced that it plans to make PROVENGE (autologous peripheral blood mononuclear cells activated with PAP-GM-CSF or sipuleucel-T) available in Europe, beginning with Germany and the United Kingdom.

3 Mar 2014

Microencapsulated drug delivery may soon revolutionize cancer treatment

Invasive and systemic cancer treatment is a necessary evil for many people with the devastating diagnosis. These patients endure therapies with ravaging side effects, including nausea, immune suppression, hair loss and even organ failure, in hopes of eradicating cancerous tissues in the body.

3 Mar 2014

Chemo and radiation can kill more cancer cells and spare healthy ones, suggests Rutgers research

What if there were a way to make chemotherapy and radiation more effective as cancer treatments than they are today, while also getting rid of debilitating side effects that patients dread? A new study led by Alexey Ryazanov, a professor of pharmacology at Rutgers Robert Wood Johnson Medical School and member of the Rutgers Cancer Institute of New Jersey, suggests the day that happens could be getting closer.

27 Feb 2014

Pacira Pharmaceuticals initiates Phase 3 clinical trial of EXPAREL in femoral nerve block

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the Phase 3 clinical trial assessing the safety and efficacy of EXPAREL® (bupivacaine liposome injectable suspension) in femoral nerve block for total knee arthroplasty met its primary efficacy endpoint.

27 Feb 2014

Study shows psychological, interpersonal effects of antidepressants have reached bizarre levels

A University of Liverpool researcher has shown that thoughts of suicide, sexual difficulties and emotional numbness as a result of anti-depressants may be more widespread than previously thought.

26 Feb 2014

Nausea News and Research

Further Reading

Study of high school players find no link between years of play and decline in neurocognitive function

Merck's NOXAFIL injection gets FDA approval for intravenous use

Study finds no link between neurocognitive function and years of football play in adolescent athletes

Investigators urge drug regulators to provide clear evidence on statins’ side effects

Orexo signs multi-year agreement with OptumRx and UnitedHealth Group

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Antares Pharma announces launch of OTREXUP to Dermatologists

New research reveals how substance abuse problems take hold in returning veterans

Incyte Corporation publishes results of Phase III trial of ruxolitinib in patients with polycythemia vera

Consumption of energy drinks may be linked with poor mental health, substance use among teens

Boehringer Ingelheim reports results from SVR12 Phase 3 trial in patients with HCV/HIV co-infection

Metallic toys, low-cost jewelry can affect children's health

Loyola surgeon successfully performs operation on patient suffering from rare disorder

New approach to breast reconstruction surgery decreases use of postoperative opioid painkiller

AbbVie's PEARL-III study meets primary, secondary endpoints in patients with chronic GT1b HCV infection

Dendreon plans to make PROVENGE available in Europe

Microencapsulated drug delivery may soon revolutionize cancer treatment

Chemo and radiation can kill more cancer cells and spare healthy ones, suggests Rutgers research

Pacira Pharmaceuticals initiates Phase 3 clinical trial of EXPAREL in femoral nerve block

Study shows psychological, interpersonal effects of antidepressants have reached bizarre levels

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News